812 related articles for article (PubMed ID: 22180306)
1. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
2. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
Voss JS; Holtegaard LM; Kerr SE; Fritcher EG; Roberts LR; Gores GJ; Zhang J; Highsmith WE; Halling KC; Kipp BR
Hum Pathol; 2013 Jul; 44(7):1216-22. PubMed ID: 23391413
[TBL] [Abstract][Full Text] [Related]
4. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Grassian AR; Pagliarini R; Chiang DY
Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
[TBL] [Abstract][Full Text] [Related]
5. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
6. IDH mutations in liver cell plasticity and biliary cancer.
Saha SK; Parachoniak CA; Bardeesy N
Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
[TBL] [Abstract][Full Text] [Related]
7. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated isocitrate dehydrogenase mutations.
Yen KE; Schenkein DP
Oncologist; 2012; 17(1):5-8. PubMed ID: 22234630
[TBL] [Abstract][Full Text] [Related]
9. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
[TBL] [Abstract][Full Text] [Related]
10. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
[TBL] [Abstract][Full Text] [Related]
12. Mutation of
Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
[No Abstract] [Full Text] [Related]
13. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Kipp BR; Voss JS; Kerr SE; Barr Fritcher EG; Graham RP; Zhang L; Highsmith WE; Zhang J; Roberts LR; Gores GJ; Halling KC
Hum Pathol; 2012 Oct; 43(10):1552-8. PubMed ID: 22503487
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
16. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
17. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
[TBL] [Abstract][Full Text] [Related]
19. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
Jang S; Chun SM; Hong SM; Sung CO; Park H; Kang HJ; Kim KP; Lee YJ; Yu E
Mod Pathol; 2014 May; 27(5):731-9. PubMed ID: 24186137
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]